Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01809028 · ClinicalTrials.gov registry record · NA

Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions

A NA study, sponsored by AdventHealth.

Completed
Registry status
NA
Development phase
62
Enrollment target

NCT01809028: Completed NA study, sponsored by AdventHealth.

NCT01809028 is a NA study that has completed, run by AdventHealth. The registered enrollment target is 62 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01809028, a NA study, has completed, sponsored by AdventHealth.

COMPLETED
Registry status
NA
Development phase
62 participants
Enrollment target

Study Summary

This study will test the amount of tissue, called "cell block", obtained from your pancreas. Patients who are asked to participate in this study have a growth (mass) in the pancreas that needs a biopsy so a diagnosis can be made. Although we usually perform 2 to 4 passes (number of times the doctor biopsies the mass), at this time we do not know the ideal number of passes needed to obtain adequate amount of tissue for making a diagnosis. The purpose of this study is to compare the amount of tissue obtained with 2 passes versus 4 passes.

Primary Outcome

The primary endpoint of the study is to compare the number of passes required to make definitive diagnosis on cell block. This will be assessed by amount (quantity) of the sample to make the diagnosis proportionate to which group the subject was randomized to (two passes versus four passes).

Interventions

  • PROCEDURE EUS FNA with 2 passes
  • PROCEDURE EUS FNA with 4 passes

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2013-02
Est. Completion 2014-01
Phase NA
AdventHealth

95 total trials

What the finished NCT01809028 record still lists

NCT01809028 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which EUS FNA with 2 passes is the first listed.

NCT01809028 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01809028 about?

NCT01809028 is a clinical study titled "Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions". This study will test the amount of tissue, called "cell block", obtained from your pancreas. Patients who are asked to participate in this study have a growth (mass) in the pancreas that needs a biopsy so a diagnosis can be made. Although we usually perform 2 to 4 passes (number of times the doctor ...

What is the current status of trial NCT01809028?

This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2013-02. Estimated completion is 2014-01.

What interventions are being tested in trial NCT01809028?

The interventions under investigation include: EUS FNA with 2 passes (PROCEDURE), EUS FNA with 4 passes (PROCEDURE).

Who is sponsoring clinical trial NCT01809028?

This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01809028's enrollment target sits among peer trials

62 1157th of 2000 higher than 837 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01809028, the US trial registry maintained by the National Library of Medicine. NCT01809028 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.